Evidence map›Paper›PMID 35356249›Full record

ReviewEvidence-based complementary and alternative medicine : eCAM2022

Emodin-Mediated Treatment of Acute Kidney Injury.

Yu Liu, Mingquan Li, LaiKuan Teh, Liangbin Zhao, Naijing Ye, Ling Wu, Lihua Wu

Open access · hybridAbstract readReview
In one paragraph

Review in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yu LiuHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.ORCID https://orcid.org/0000-0002-9295-8384
Mingquan LiHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.ORCID https://orcid.org/0000-0001-9402-4406
LaiKuan TehDepartment of Allied Health Sciences Faculty of Science Universiti Tunku Abdul Rahman (UTAR), Kampar, Perak, Malaysia.ORCID https://orcid.org/0000-0003-2300-9887
Liangbin ZhaoHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.ORCID https://orcid.org/0000-0003-3786-0015
Naijing YeHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.ORCID https://orcid.org/0000-0001-8868-0183
Ling WuHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.ORCID https://orcid.org/0000-0002-8222-4125
Lihua WuHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.ORCID https://orcid.org/0000-0001-6112-4195
Universiti Tunku Abdul Rahman · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute kidney injury (AKI), a common condition associated with a high mortality rate, is characterized by declined glomerular filtration rate, retention of nitrogen products, and disturbances in balance of water, electrolyte, and acid-base. Up to date, there is no effective treatment for AKI. Despite the continuous improvement in blood purification techniques, a considerable proportion of patients with AKI still progress to end-stage renal disease. These patients with advanced stage of end-stage renal disease will require long-term renal replacement therapy, which places a heavy burden on the family and the society. In recent years, the use of traditional Chinese medicine (TCM) in AKI management has been gradually increasing. Clinical evidence has demonstrated that three-month treatment with TCM produced better clinical outcomes in terms of clinical effectiveness rate and improvement in renal function (serum creatinine, neutrophil gelatinase-associated lipocalin, and cystatin C) compared with Western medicine. Rhubarb is a commonly used herb in TCM for the treatment of AKI. The main active component of rhubarb is emodin, which was first recorded in Shennong's Classic of Materia Medica. It has been shown that emodin has a variety of pharmacological activities including antibacterial, anti-inflammatory, antiulcer, and immunosuppressive effects. Emodin has been found to be effective against renal fibrosis and has been widely studied for its effects on kidney diseases such as diabetic nephropathy, renal fibrosis, and AKI. Moreover, promising results have been obtained from these studies. In this study, the results obtained from research on the use of emodin for AKI treatment has been reviewed.

Identifiers

PMID35356249
PMCPMC8959961
OpenAlexW4221127039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.